{"disease":{"id":"mild-to-moderate-covid-19","name":"mild to moderate covid 19"},"drugs":{"marketed":[{"drug_id":"nirmatrelvir","indication_name":"Treatment of mild-to-moderate COVID-19","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paxlovid (Copackaged)","generic_name":"nirmatrelvir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":"2362.0","mechanism":"Paxlovid works by binding to the main protease enzyme of the SARS-CoV-2 virus, preventing it from replicating."},{"drug_id":"nirmatrelvir-ritonavir","indication_name":"Treatment of mild to moderate COVID-19 in adults and pediatric patients (5 years of age and older) who weigh at least 40 kg.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"nirmatrelvir-ritonavir","generic_name":"nirmatrelvir-ritonavir","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 protease enzyme","drug_class":"Protease inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"part-a-atm-avi-single-dose-cohorts-1-4","indication_name":"Treatment of COVID-19 in adults and pediatric patients (12 years of age and older) who are at high risk of progression to severe COVID-19, including those who are hospitalized due to COVID-19 or who have mild to moderate COVID-19 with at least one risk factor for progression to severe COVID-19 (e.g., older age, certain chronic medical conditions)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Part A: ATM-AVI Single Dose, Cohorts 1-4","generic_name":"part-a-atm-avi-single-dose-cohorts-1-4","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05582629","title":"JT001 (VV116) for the Treatment of COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1369,"lead_sponsor_name":"Shanghai Vinnerna Biosciences Co., Ltd.","has_results":false},{"nct_id":"NCT05620160","title":"Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1359,"lead_sponsor_name":"Guangdong Raynovent Biotech Co., Ltd","has_results":false},{"nct_id":"NCT06197217","title":"Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1350,"lead_sponsor_name":"Westlake Pharmaceuticals (Hangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04521296","title":"Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":432,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT04711863","title":"Fluvoxamine for Adults With Mild to Moderate COVID-19","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":400,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT05242042","title":"JT001 (VV116) for the Early Treatment of COVID-19","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":381,"lead_sponsor_name":"Shanghai JunTop Biosciences Co., LTD","has_results":false},{"nct_id":"NCT04414124","title":"A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19","phase":"NA","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Kaleido Biosciences","has_results":false},{"nct_id":"NCT05947812","title":"A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":148,"lead_sponsor_name":"60P Australia Pty Ltd","has_results":false},{"nct_id":"NCT05941793","title":"A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Oneness Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT04486482","title":"A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function","phase":"NA","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Kaleido Biosciences","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}